Document Detail

Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis.
MedLine Citation:
PMID:  7706829     Owner:  NLM     Status:  MEDLINE    
To determine if cytokine immunotherapy accelerates the response to conventional treatment in visceral leishmaniasis (kala-azar), previously untreated Indian patients were given antimony for 30 days (n = 15) or antimony plus interferon-gamma (IFN-gamma; n = 16). After 10 days, 10 (63%) of 16 patients treated with antimony plus IFN-gamma versus 1 (7%) of 15 randomized to antimony alone were considered cured of parasites (P < .005). On day 20, 14 (93%) of 15 versus 6 (40%) of 15 patients, respectively, were apparent clinical cures (P < .006), and treatment was discontinued early in the 14 IFN-gamma treated responders. Day 30 apparent cure rates (100% vs. 73%) and 6-month ultimate cure responses (87% vs. 60%) were higher in IFN-gamma-treated patients but not statistically different from controls (P > .05). All 13 IFN-gamma-treated subjects who were cured (12 of whom received therapy for 20 days) have remained healthy with follow-up of 14-24 months (mean, 18.9). These results indicate that IFN-gamma successfully accelerates the parasitologic and clinical response to antimony treatment, an effect that should permit shortening the duration of conventional therapy in previously untreated kala-azar.
S Sundar; F Rosenkaimer; M L Lesser; H W Murray
Related Documents :
352419 - Combined therapy of human interferon (hi) and secretory immunoglobulin (s-iga) in the t...
19950239 - Use of epoetin beta during combination therapy of infection with hepatitis c virus with...
3356149 - Analysis of duration of response: a problem of oncology trials.
15911439 - Spontaneous recovery of hemoglobin and neutrophil levels in japanese patients on a long...
10860129 - Long-term patient adherence to antiretroviral therapy.
19812449 - Efficacy and safety of darunavir/ritonavir in treatment-experienced hiv type-1 patients...
22980309 - Outcome of patients aged ≥80 years undergoing combined aortic valve replacement and c...
12237059 - A historical appraisal of the use of cryopreserved and glycerol-preserved allograft ski...
23522679 - Assessment of heifer grazing experience on short-term adaptation to pasture and perform...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of infectious diseases     Volume:  171     ISSN:  0022-1899     ISO Abbreviation:  J. Infect. Dis.     Publication Date:  1995 Apr 
Date Detail:
Created Date:  1995-05-05     Completed Date:  1995-05-05     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0413675     Medline TA:  J Infect Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  992-6     Citation Subset:  AIM; IM    
Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimony / therapeutic use*
Child, Preschool
Drug Therapy, Combination
Interferon-gamma, Recombinant / therapeutic use*
Leishmania donovani / isolation & purification
Leishmaniasis, Visceral / drug therapy*,  parasitology
Middle Aged
Spleen / parasitology
Grant Support
Reg. No./Substance:
0/Interferon-gamma, Recombinant; 7440-36-0/Antimony

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cross-reactivity of human Toxoplasma-specific T cells: implications for development of a potential i...
Next Document:  Abnormal lymphatic function in presymptomatic bancroftian filariasis.